Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer
This study aims to find out if a medicine called durvalumab can help people with muscle-invasive bladder cancer. Participants will have already finished a combination of treatments, which include surgery, chemotherapy, and radiotherapy. Durvalumab is a type of immunotherapy that works by helping your body's immune system recognise and fight cancer cells more effectively. Researchers want to see if adding durvalumab after these standard treatments can help slow down the cancer's growth or cause cancer cells to die. It's currently unclear if this extra step is beneficial for bladder cancer patients who have already completed other therapies.
במבט חטוף
על מה המחקר הזה?
This study is looking into a new approach for treating bladder cancer, specifically for people whose cancer has grown into the muscle of the bladder. This type of cancer is called muscle-invasive bladder cancer. Many people with this cancer will have a combination of treatments, which might include surgery, chemotherapy, and radiotherapy. These treatments are often given one after the other, or sometimes together. While these treatments are effective for many, researchers are always looking for ways to improve outcomes and give patients the best chance of recovery.
The main idea behind this study is to see if adding a drug called durvalumab *after* you've already completed your surgery, chemotherapy, and radiotherapy, can make a difference. Durvalumab is a type of medicine known as immunotherapy. Immunotherapy works by helping your body's own immune system become stronger and better at finding and fighting cancer cells. Think of it like giving your immune system a boost to recognise the cancer as a threat and attack it.
We know durvalumab has been tested in other types of cancer and has shown promise in helping the immune system reactivate and detect cancer. For bladder cancer, we want to understand if using durvalumab after standard treatments can help slow down the cancer's growth, or even cause cancer cells to die. At the moment, we don't know for sure if adding durvalumab at this stage will be helpful for people with bladder cancer who have completed their initial treatments, which is why this study is so important.
נקודות עיקריות
- This study explores a new treatment option for bladder cancer.
- It tests an immunotherapy drug called durvalumab after standard treatments.
- The goal is for the immune system to better fight cancer cells.
- It's for people who have completed surgery, chemotherapy, and radiotherapy.
- ההשתתפות היא בהתנדבות, ואתה יכול לפרוש בכל עת.
מי עשוי להיות זכאי?
To be part of this study, you would generally need to have been diagnosed with bladder cancer that has grown into the muscle layer (muscle-invasive bladder cancer). The cancer should not have spread to other parts of your body, which doctors call metastatic disease. You must be at least 18 years old, generally fit and well enough to take part, and weigh more than 30 kilograms.
A key requirement is that you will have already completed your initial treatment for bladder cancer, which includes surgery, chemotherapy, and radiotherapy. It's important that you are able to start the study treatment within six weeks after finishing your previous treatments. You will also need to have healthy enough blood counts, kidney function, and liver function.
Your doctors will need to check your medical records, including details of your bladder cancer diagnosis and previous treatments, to ensure you meet all the necessary requirements for the study. There are specific criteria regarding the type of bladder cancer you have, and certain prior treatments that might mean you can't join.
האם מחקר זה יכול להתאים לך?
ענה על השאלות המהירות הללו כדי לבדוק אם אתה עשוי להיות זכאי. זהו מדריך בלבד — צוות המחקר מקבל את ההחלטה הסופית.
- האם אתה בן 18 או יותר?
- Do you have muscle-invasive bladder cancer that hasn't spread?
- Have you already completed surgery, chemotherapy, and radiotherapy for your bladder cancer?
- Are you generally well and fit enough for treatment?
- Can you start the study treatment within about 6 weeks of finishing your previous treatments?
מה כרוך בהשתתפות?
If you decide to take part in this study, you would receive the drug durvalumab after you've finished your initial treatment of surgery, chemotherapy, and radiotherapy. The exact schedule for taking durvalumab and how long you'd be on it would be explained by the study team. You would have regular appointments at the hospital for check-ups, blood tests, and to receive the study drug, which is usually given through a drip.
These appointments are important to monitor your health, see how you're responding to the treatment, and check for any side effects. The study team will tell you how often these visits will be and what tests you'll have. The total duration of your participation in the study, including treatment and follow-up, will be clearly outlined by the researchers.
סיכונים ותועלות פוטנציאליים
Locations (31)
- Tom Baker Cancer Centreמיקוד מאומתקלגרי, קנדה
- מכון הסרטן קרוסמיקוד מאומתאדמונטון, קנדה
- BCCA - Vancouver Cancer Centreמיקוד מאומתונקובר, קנדה
- Health Sciences Northמיקוד מאומתGreater Sudbury, Canada
- Juravinski Cancer Centre at Hamilton Health Sciencesמיקוד מאומתהמילטון, קנדה
- Kingston Health Sciences Centreמיקוד מאומתקינגסטון, קנדה
- London Regional Cancer Programמיקוד מאומתלונדון, קנדה
- Stronach Regional Health Centre at Southlakeמיקוד מאומתNewmarket, Canada
- Ottawa Hospital Research Instituteמיקוד מאומתאוטווה, קנדה
- Thunder Bay Regional Health Sciences Centre/מיקוד מאומתThunder Bay, Canada
- University Health Networkמיקוד מאומתטורונטו, קנדה
- The Jewish General Hospitalמיקוד מאומתמונטריאול, קנדה
שאלות נפוצות
What is durvalumab?
Durvalumab is a medicine that helps your body's immune system recognise and fight cancer cells.
מי יכול להצטרף למחקר זה?
This study is for adults with muscle-invasive bladder cancer who have already finished surgery, chemotherapy, and radiotherapy.
What does 'trimodality therapy' mean?
It means receiving three types of treatment: surgery, chemotherapy, and radiotherapy for your cancer.
Will I still get my usual cancer care if I don't join?
Yes, taking part in a study is completely voluntary and will not affect your standard medical care either way.
כמה זמן יימשך המחקר?
The study team will tell you the expected length of treatment and follow-up during your discussions with them.
כיצד לגלות עוד
תמיד התייעץ עם רופא המשפחה או המומחה שלך לפני שתחליט להשתתף במחקר.
דיון
דיון קהילתי
מופעל על ידי הפורום שלנו ב community.patient.info. אנא היו מכבדים — זה אינו ייעוץ רפואי.